ArticleNPJ precision oncology2026

GLP-1 receptor agonist targets an AMPKα1-HIF1α-PFKFB3 metabolic vulnerability and enhances Lenvatinib response in hepatocellular carcinoma.

Takayuki Noma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.